These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29991719)

  • 1. The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain.
    Eriksson Y; Boström M; Sandelius Å; Blennow K; Zetterberg H; Kuhn G; Kalm M
    Cell Death Dis; 2018 Jul; 9(7):775. PubMed ID: 29991719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Allergic Drug Suppressed Pancreatic Carcinogenesis via Down-Regulation of Cellular Proliferation.
    Kachi K; Kato H; Naiki-Ito A; Komura M; Nagano-Matsuo A; Naitoh I; Hayashi K; Kataoka H; Inaguma S; Takahashi S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
    Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
    Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
    Mohamed MZ; Zenhom NM
    Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma.
    Kotani H; Kishi R; Mouri A; Sashio T; Shindo J; Shiraki A; Hiramatsu T; Iwata S; Taniguchi H; Nishiyama O; Iwata M; Suzuki R; Gonda H; Niwa T; Kondo M; Hasegawa Y; Kume H; Noda Y
    J Clin Pharm Ther; 2012 Feb; 37(1):112-6. PubMed ID: 21385196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.
    Michael J; Zirknitzer J; Unger MS; Poupardin R; Rieß T; Paiement N; Zerbe H; Hutter-Paier B; Reitsamer H; Aigner L
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma.
    Diamant Z; Grootendorst DC; Veselic-Charvat M; Timmers MC; De Smet M; Leff JA; Seidenberg BC; Zwinderman AH; Peszek I; Sterk PJ
    Clin Exp Allergy; 1999 Jan; 29(1):42-51. PubMed ID: 10051701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of montelukast on the expression of neurokinin-1 receptor in young asthmatic rats with airway remodeling].
    Wei B; Shang YX; Li M; Zhang H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Apr; 15(4):298-301. PubMed ID: 23607955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma.
    Yüksel B; Aydemir C; Ustündag G; Eldeş N; Kutsal E; Can M; Demirtaş S; Tomaç N
    Turk J Pediatr; 2009; 51(5):460-5. PubMed ID: 20112601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus.
    Han J; Jia Y; Takeda K; Shiraishi Y; Okamoto M; Dakhama A; Gelfand EW
    Am J Respir Crit Care Med; 2010 Aug; 182(4):455-63. PubMed ID: 20442434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
    Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
    Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
    Leff JA; Busse WW; Pearlman D; Bronsky EA; Kemp J; Hendeles L; Dockhorn R; Kundu S; Zhang J; Seidenberg BC; Reiss TF
    N Engl J Med; 1998 Jul; 339(3):147-52. PubMed ID: 9664090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug.
    Gelosa P; Bonfanti E; Castiglioni L; Delgado-Garcia JM; Gruart A; Fontana L; Gotti M; Tremoli E; Lecca D; Fumagalli M; Cimino M; Aigner L; Abbracchio MP; Sironi L
    Pharmacol Res; 2019 Apr; 142():223-236. PubMed ID: 30818044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study.
    Becker AB; Kuznetsova O; Vermeulen J; Soto-Quiros ME; Young B; Reiss TF; Dass SB; Knorr BA;
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):800-7. PubMed ID: 16802767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast in pediatric asthma management.
    Walia M; Lodha R; Kabra SK
    Indian J Pediatr; 2006 Apr; 73(4):275-82. PubMed ID: 16816486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
    Yu GL; Wei EQ; Zhang SH; Xu HM; Chu LS; Zhang WP; Zhang Q; Chen Z; Mei RH; Zhao MH
    Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
    Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A
    Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of montelukast on morphological changes in neurons after ischemic injury].
    Wang XX; Zhang XY; Huang XQ; Yu SY; Zhao R; Fang SH; Lu YB; Zhang WP; Wei EQ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 May; 41(3):259-66. PubMed ID: 22723160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Niemi M; Neuvonen PJ
    Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
    Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
    Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.